These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

149 related articles for article (PubMed ID: 16288850)

  • 1. Cost-effectiveness of add-on lamotrigine therapy in clinical practice.
    Knoester PD; Boendermaker AJ; Egberts AC; Hekster YA; Keyser A; Severens JL; Renier WO; Deckers CL
    Epilepsy Res; 2005 Dec; 67(3):143-51. PubMed ID: 16288850
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Cost-utility analysis of rufinamide versus topiramate and lamotrigine for the treatment of children with Lennox-Gastaut Syndrome in the United Kingdom.
    Verdian L; Yi Y
    Seizure; 2010 Jan; 19(1):1-11. PubMed ID: 19942457
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cost-effectiveness model of adjunctive lamotrigine for the treatment of epilepsy.
    Markowitz MA; Mauskopf JA; Halpern MT
    Neurology; 1998 Oct; 51(4):1026-33. PubMed ID: 9781524
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effectiveness of lamotrigine in clinical practice: results of a retrospective population-based study.
    Knoester PD; Keyser A; Renier WO; Egberts AC; Hekster YA; Deckers CL
    Epilepsy Res; 2005 Jun; 65(1-2):93-100. PubMed ID: 16023833
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cost-effectiveness of add-on therapy with pregabalin in patients with refractory partial epilepsy.
    Vera-Llonch M; Brandenburg NA; Oster G
    Epilepsia; 2008 Mar; 49(3):431-7. PubMed ID: 17822431
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Adjunctive lamotrigine therapy in patients with refractory seizures: a lifetime cost-utility analysis.
    Messori A; Trippoli S; Becagli P; Cincotta M; Labbate MG; Zaccara G
    Eur J Clin Pharmacol; 1998 Feb; 53(6):421-7. PubMed ID: 9551700
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A cost-effectiveness decision model for antiepileptic drug treatment in newly diagnosed epilepsy patients.
    Knoester PD; Deckers CL; Termeer EH; Boendermaker AJ; Kotsopoulos IA; de Krom MC; Keyser T; Renier WO; Hekster YA; Severens HL
    Value Health; 2007; 10(3):173-82. PubMed ID: 17532810
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The use of lamotrigine and other antiepileptic drugs in paediatric patients at a Malaysian hospital.
    Ab Rahman AF; Ibrahim MI; Ismail HI; Seng TB
    Pharm World Sci; 2005 Oct; 27(5):403-6. PubMed ID: 16341748
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Adjunctive therapy in epilepsy: a cost-effectiveness comparison of two AEDs.
    Selai CE; Smith K; Trimble MR
    Seizure; 1999 Feb; 8(1):8-13. PubMed ID: 10091841
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Patterns of lamotrigine use in daily clinical practice during the first 5 years after introduction in the Netherlands.
    Knoester PD; Belitser SV; Deckers CL; Keyser A; Renier WO; Egberts AC; Hekster YA
    J Clin Pharm Ther; 2004 Apr; 29(2):131-8. PubMed ID: 15068401
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Lamotrigine adjunctive therapy among children and adolescents with primary generalized tonic-clonic seizures.
    Trevathan E; Kerls SP; Hammer AE; Vuong A; Messenheimer JA
    Pediatrics; 2006 Aug; 118(2):e371-8. PubMed ID: 16847080
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Adjunctive therapy in epilepsy: a cost-effectiveness comparison of alternative treatment options.
    O'Neill BA; Trimble MR; Bloom DS
    Seizure; 1995 Mar; 4(1):37-44. PubMed ID: 7788105
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cost-effectiveness analysis for the use of serum antiepileptic drug level monitoring in children diagnosed with structural-metabolic epilepsy.
    Salih MR; Bahari MB; Shafie AA; Hassali MA; Al-Lela OQ; Abd AY; Ganesan VM
    Epilepsy Res; 2013 Mar; 104(1-2):151-7. PubMed ID: 23103061
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Economic evaluation of anti-epileptic drug therapies with specific focus on teratogenic outcomes.
    Jentink J; Boersma C; de Jong-van den Berg LT; Postma MJ
    J Med Econ; 2012; 15(5):862-8. PubMed ID: 22494266
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The impact on health outcomes and healthcare utilisation of switching to generic medicines consequent to reference pricing: the case of lamotrigine in New Zealand.
    Lessing C; Ashton T; Davis P
    Appl Health Econ Health Policy; 2014 Oct; 12(5):537-46. PubMed ID: 25005492
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cost-effectiveness of pediatric epilepsy surgery compared to medical treatment in children with intractable epilepsy.
    Widjaja E; Li B; Schinkel CD; Puchalski Ritchie L; Weaver J; Snead OC; Rutka JT; Coyte PC
    Epilepsy Res; 2011 Mar; 94(1-2):61-8. PubMed ID: 21306874
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Lamotrigine-valproic acid combination therapy for medically refractory epilepsy.
    Moeller JJ; Rahey SR; Sadler RM
    Epilepsia; 2009 Mar; 50(3):475-9. PubMed ID: 19054403
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The economic consequences of generic substitution for antiepileptic drugs in a public payer setting: the case of lamotrigine.
    Duh MS; Andermann F; Paradis PE; Weiner J; Manjunath R; Crémieux PY
    Dis Manag; 2007 Aug; 10(4):216-25. PubMed ID: 17718660
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Cost-effectiveness of epilepsy surgery in a cohort of patients with medically intractable partial epilepsy--preliminary results].
    Picot MC; Neveu D; Kahane P; Crespel A; Gélisse P; Hirsch E; Derambure P; Dupont S; Landré E; Chassoux F; Valton L; Vignal JP; Marchal C; Rougier A; Lamy C; Semah F; Biraben A; Arzimanoglou A; Petit J; Thomas P; Dujols P; Ryvlin P
    Rev Neurol (Paris); 2004 Jun; 160 Spec No 1():5S354-67. PubMed ID: 15331984
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Identification of adverse reactions that can occur on substitution of generic for branded lamotrigine in patients with epilepsy.
    Makus KG; McCormick J
    Clin Ther; 2007 Feb; 29(2):334-41. PubMed ID: 17472825
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.